Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | AOC3 | Q16853 | 18/20 | 0.67 |
| ▸ | AOC2 | O75106 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020729 | 1.00 | KCNH2 (0.68) | KCNH2AOC3AOC2 | |
| SCHEMBL30020733 | 0.92 | AOC3 (0.58) | KCNH2AOC3 | |
| SCHEMBL17621639 | 0.92 | AOC3 (0.58) | KCNH2AOC3 | |
| SCHEMBL20924438 | 0.85 | AOC3 (0.75) | KCNH2AOC3AOC2 | |
| SCHEMBL22997639 | 0.81 | AOC3 (0.72) | KCNH2AOC3AOC2 | |
| SCHEMBL16048921 | 0.81 | KCNH2 (1.00) | KCNH2AOC3AOC2 | |
| SCHEMBL30026367 | 0.81 | KCNH2 (1.00) | KCNH2AOC3AOC2 | |
| SCHEMBL17075552 | 0.80 | AOC3 (1.00) | KCNH2AOC3AOC2 | |
| SCHEMBL16067948 | 0.80 | AOC3 (1.00) | KCNH2AOC3AOC2 | |
| SCHEMBL20924559 | 0.78 | AOC3 (0.64) | KCNH2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | claimed |
| CN-111032029-A | Vascular adhesion protein-1 inhibitors for the prevention or treatment of migraine | 普罗克斯马根有限责任公司 | 2020-04-17 | — | — | CN | claimed |
| EP-3634393-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | PROXIMAGEN, LLC (US) | 2020-04-15 | — | — | EP | claimed |
| EP-3194389-B1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018224837-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | Proximagen Group Limited (GB) | 2018-12-13 | — | — | WO | claimed |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-09-28 | — | — | US | claimed |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PROXIMAGEN, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PROXIMAGEN, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3194389-B1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3194389-B1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-09-28 | — | — | US | disclosed |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-09-28 | — | — | US | disclosed |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-09-28 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | KCNH2 1764/4885AOC3 55/4885AOC2 59/4885 |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PNPO, SQOR, HAO1 | KCNH2 492/4885AOC3 5/4885AOC2 10/4885 |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, SMOX | KCNH2 1505/4885AOC3 4/4885AOC2 5/4885 |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PNPO, SQOR, HAO1 | KCNH2 492/4885AOC3 5/4885AOC2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.